
Opinion|Videos|January 10, 2025
Tailored Support: The Role of Industry-Provided Services in Lymphoma Care
Panelists discuss how they assess the individual support needs of patients diagnosed with diffuse large B-cell lymphoma or follicular lymphoma and describe an ideal model for industry-provided support services for these patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you assess the individual support needs of each patient when they are diagnosed with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL)?
- In a perfect world, describe what industry-provided support services look like for patients diagnosed with DLBCL and FL.
Advertisement
Related to this article

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
Advertisement
Advertisement

